BioAge宣布扩大口服NLRP3抑制剂BGE-102适应症范围,拟于2026年中启动针对糖尿病黄斑水肿患者的1b/2a期概念验证临床试验

美股速递
Jan 20

BioAge Labs Inc.近日公布其口服NLRP3抑制剂BGE-102的适应症拓展计划。该企业拟于2026年中期启动一项针对糖尿病黄斑水肿患者的1b/2a期概念验证临床试验,旨在评估BGE-102在该疾病领域的治疗潜力。

此次适应症扩展标志着BioAge在炎症性疾病治疗领域的战略布局进一步深化。糖尿病黄斑水肿作为糖尿病常见的视网膜并发症,目前临床治疗选择仍存在局限性,BGE-102的介入有望为患者提供新的治疗方向。

临床试验将重点验证BGE-102通过抑制NLRP3炎症小体通路,在缓解视网膜炎症和血管渗漏方面的疗效。若试验结果达到预期,将为企业后续的产品管线拓展奠定重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10